Pharmacokinetics of amphotericin B colloidal dispersion in critically ill patients with cholestatic liver disease

scientific article

Pharmacokinetics of amphotericin B colloidal dispersion in critically ill patients with cholestatic liver disease is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1128/AAC.00690-12
P932PMC publication ID3457374
P698PubMed publication ID22850517

P50authorMichael JoannidisQ88062375
P2093author name stringStefan Weiler
Stefan Dunzendorfer
Romuald Bellmann
Elisabeth Überlacher
Eva Stienecke
Julia Schöfmann
P2860cites workAcute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injuryQ21195041
Invasive aspergillosis in the intensive care unitQ28306909
Amphotericin B colloidal dispersion. Pre-clinical reviewQ33679607
Comparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation to ratsQ33744215
Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humansQ34113512
Transection of the oesophagus for bleeding oesophageal varicesQ34211834
Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine.Q34480866
Pharmacokinetics of liposomal amphotericin B (Ambisome) in critically ill patientsQ35136556
Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/Q37164067
Pulmonary epithelial lining fluid concentrations after use of systemic amphotericin B lipid formulations.Q37409856
Influence of albumin dialysis on pharmacokinetics of amphotericin B colloidal dispersion and amphotericin B lipid complex.Q38463373
Altered pharmacokinetics of voriconazole in a patient with liver cirrhosis.Q42627513
Determination of amphotericin B, liposomal amphotericin B, and amphotericin B colloidal dispersion in plasma by high-performance liquid chromatographyQ43725025
Amphotericin B lipid formulations in critically ill patients on continuous veno-venous haemofiltrationQ44342593
Differences in pharmacokinetics of amphotericin B lipid formulations despite clinical equivalenceQ44453839
Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunctionQ46711313
Amphotericin B tissue distribution in autopsy material after treatment with liposomal amphotericin B and amphotericin B colloidal dispersionQ48575634
Amphotericin B in the treatment of Candida cholecystitisQ50156282
AmBisome (liposomal amphotericin B): a comparative review.Q52531516
Excretion Pathways of Amphotericin BQ66962115
Biliary excretion of amphotericin B deoxycholate and amphotericin B lipid complexQ73133659
Anidulafungin does not require dosage adjustment in subjects with varying degrees of hepatic or renal impairmentQ80050361
Invasive aspergillosis in critically ill patients without malignancyQ80269940
Pharmacokinetics of voriconazole during continuous venovenous haemodiafiltrationQ81251244
Pharmacokinetics of caspofungin in a critically ill patient with liver cirrhosisQ84264833
P433issue10
P407language of work or nameEnglishQ1860
P921main subjectamphotericin BQ412223
pharmacokineticsQ323936
P304page(s)5414-5418
P577publication date2012-07-30
P1433published inAntimicrobial Agents and ChemotherapyQ578004
P1476titlePharmacokinetics of amphotericin B colloidal dispersion in critically ill patients with cholestatic liver disease
P478volume56

Reverse relations

cites work (P2860)
Q26740363Fungal diseases: could nanostructured drug delivery systems be a novel paradigm for therapy?
Q92446036Lipid Systems for the Delivery of Amphotericin B in Antifungal Therapy
Q38681635Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients
Q60175850Pre-Existing Liver Disease and Toxicity of Antifungals
Q35148135Therapeutic monitoring of amphotericin B in Saudi ICU patients using UPLC MS/MS assay

Search more.